Navigation Links
DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Date:10/24/2011

TORONTO, Oct. 24, 2011 /PRNewswire/ -- DLVR Therapeutics Inc. ("DLVR") - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle -announced today that the Company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support.  MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company.  The additional funds will be used by DLVR to advance its small molecule chemotherapeutic program towards a pre-clinical regulatory package and continue development of its small interfering RNA (siRNA) program.

"This additional financing highlights the significant potential of our nanoparticle delivery platform approach," stated Mr. Frank Gleeson, President and CEO of DLVR. "Our nanoparticles offer a unique and selective delivery of the payload to the cytosol of the intended target reducing undesired side effects.  MaRS Innovation has recognized this great potential and its investment enables us to accelerate our efforts to advance a chemotherapeutic candidate into IND-enabling studies."

The company's initial development strategy is focused on exploiting the natural targeting approach of DLVR's technology to cancer cells.  With proof-of-concept studies completed, the company is well on its way to identifying a clinical candidate while securing partnerships to further develop delivery of siRNA payloads.  Co-incident with the transaction, Raphael (Rafi) Hofstein, PhD, President and CEO of MaRS Innovation, will join DLVR's board of directors and Parimal Nathwani, Vice-President of MaRS Innovation will become a member of the company's management team in a business development capacity.

"We are very pleased to be joining UHN and OICR in supporting this new and exciting company," stated Dr. Hofstein.  "DLVR pr
'/>"/>

SOURCE DLVR Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
2. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
3. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
4. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
5. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
6. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
7. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
8. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
9. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
10. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
11. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 ... (XNA, Chassis, Oligos, Enzymes, Cloning kits), Technology ... Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global ... major market drivers, threats, opportunities, and challenges. ... 46 figures spread through 185 pages and ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4
... Pharmaceuticals, Inc.,(Nasdaq: AMLN ) will be presenting at ... 2008 at 10:00 a.m. PT in Las Vegas. Michael,York, ... providing a corporate overview., The live presentation and ... made available following the event. The webcast and,recording will ...
... Agreement expands Dermagraft presence within government channels, ... May 7 Advanced,BioHealing, Inc. (ABH) and ... on the promotion of Dermagraft(R) within the ... of the agreement,Regenesis will provide its specialized ...
... Demonstrate Abbott,s Most Advanced NNR Candidate ABT-089 ... Adults With ADHD, ABBOTT PARK, Ill., May ... leading scientists will present new Phase II data ... agonist, is a,potentially effective and safe treatment for ...
Cached Biology Technology:Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 2Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 3Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 2Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 3Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 4Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 5
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... a tiny ball of ice, a minimally invasive interventional ... caused by nerve damage, according to data being presented ... Meeting in New Orleans. "Cryoneurolysis could have big ... neuralgia, which can be unbearable and is very difficult ...
... reopens completely blocked bowel arteries, preventing damage and ... severe pain and leads to excessive weight loss, ... Interventional Radiology,s 38th Annual Scientific Meeting in New ... saves lives," said Daniel A. Leung, M.D., program ...
... A genetic analysis of the avian flu virus responsible ... virus evolving to adapt to human cells, raising concern about ... The collaborative study, conducted by a group led by Masato ... Infectious Diseases, and Yoshihiro Kawaoka of the University of Wisconsin-Madison ...
Cached Biology News:Freezing nerves knocks pain out cold 2Stenting blocked bowel arteries saves lives 2New bird flu strain seen adapting to mammals, humans 2
... Round Well Plate Sterile ... wide range of 384-well ... high-throughput screening and research. ... assays and are suitable ...
Request Info...
Aldolase A (N-15)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: